Refine
Year of publication
Document Type
- Preprint (719)
- Article (581)
- Conference Proceeding (5)
- Report (1)
- Working Paper (1)
Has Fulltext
- yes (1307)
Is part of the Bibliography
- no (1307)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- SARS-CoV-2 (6)
- ALICE experiment (4)
- COVID-19 (4)
- COVID19-NMR (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- Solution NMR spectroscopy (4)
- 5′-UTR (3)
- ALICE (3)
- Heavy Ions (3)
- Heavy Quark Production (3)
- Jets and Jet Substructure (3)
- anal cancer (3)
- chemoradiotherapy (3)
- p53 (3)
- pp collisions (3)
- risk factors (3)
- Beauty production (2)
- Biochemistry (2)
- C-reactive protein (2)
- Charm physics (2)
- Collectivity (2)
- Correlation (2)
- Diffraction (2)
- Elastic scattering (2)
- Elliptic flow (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- HIV (2)
- Head and neck cancer (2)
- Heavy-ion collisions (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Patterns of care (2)
- Pb–Pb collisions (2)
- Postoperative radiochemotherapy (2)
- Precipitation inhibition (2)
- QCD (2)
- Quarkonium (2)
- RNA (2)
- Radiotherapy (2)
- Relativistic heavy-ion collisions (2)
- Shear viscosity (2)
- Single electrons (2)
- Supersaturation (2)
- Target validation (2)
- Treatment (2)
- albumin (2)
- biomarker (2)
- cervical cancer (2)
- chemotherapy (2)
- clinically important restrictions and symptoms (2)
- drug resistance (2)
- inflammation (2)
- local control (2)
- nutlin-3 (2)
- observational study (2)
- portal hypertension (2)
- rare disease (2)
- supersaturation (2)
- 19F (1)
- 5'-UTR (1)
- 5_SL4 (1)
- 900 GeV (1)
- ACLF (1)
- ADHD (1)
- AIDS (1)
- ALICE detector (1)
- Adolescents (1)
- Advanced stage (1)
- Anal cancer (1)
- Anti-kaon–nucleon physics (1)
- Anti-nuclei (1)
- Archaeogeophysics (1)
- Atomic and molecular interactions with photons (1)
- Attention-Deficit/Hyperactivity Disorder (ADHD) (1)
- Azores Archipelago (1)
- B-slope (1)
- Biochemistry and chemical biology (1)
- Biodiversity (1)
- Bioenabling formulations (1)
- Biomarker (1)
- Blood sample handling (1)
- Boosted Jets (1)
- CAR (1)
- CD8 (1)
- CD8+ tumor infiltrating lymphocytes (1)
- CNS toxicity (1)
- COVID (1)
- COVID‐19 (1)
- CRT (1)
- CXCR4 (1)
- Cancer genomics (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Chemical composition (1)
- Chemical physics (1)
- Chemoradiotherapy (1)
- Coalescence (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Comparative genomics (1)
- Comparison with QCD (1)
- Complicated stage (1)
- Conduct disorder (1)
- Conformational trapping (1)
- Contingent Negative Variation, CNV (1)
- Continuous Performance Test, CPT (1)
- Costs (1)
- Covid19-nmr (1)
- Critical point (1)
- Cue-P3 (1)
- DKTK-ROG (1)
- DNA-PAINT (1)
- Data management (1)
- Data sharing (1)
- Demolition emissions (1)
- Depression (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Direct oral anticoagulation (1)
- Direct reactions (1)
- Disease Activity (1)
- E. colo (1)
- EP300 (1)
- EWSR1 (1)
- Early Rheumatoid Arthritis (1)
- Ecosystems (1)
- Electron-pion identification (1)
- Electronic structure of atoms and molecules (1)
- Electroweak interaction (1)
- Emotion regulation (1)
- Endocannabinoids (1)
- Enthalpy (1)
- Environment (1)
- Epilepsy (1)
- Ethics Committees/Consultation (1)
- European distribution (1)
- Event related potentials (1)
- Evolution (1)
- FBS (1)
- FOXO1 (1)
- Family Physician (1)
- Females (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- First-line regimen (1)
- Forschung (1)
- Full waveform (1)
- Fungi (1)
- G protein-coupled receptor (GPCR) (1)
- Gene expression profiling (1)
- Gene fusion (1)
- Glioblastoma survival (1)
- Groomed jet radius (1)
- HBT (1)
- HNO (1)
- HNSCC (1)
- HPV (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Health information (1)
- Health-seeking behaviour (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Helpline (1)
- High-throughput screening (1)
- Higher moments (1)
- HoLEP (1)
- Holmium laser enucleation (1)
- Hsp70 (1)
- ICON model (1)
- IHC (1)
- Imrt (1)
- In vitro selection (1)
- Incidental prostate cancer (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- Interpretation (1)
- Invariant Mass Distribution (1)
- Inversion (1)
- Ionisation energy loss (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- KCGS (1)
- Kaonic nuclei (1)
- Ki-67/MIB1 (1)
- LEOSS (1)
- Lehre (1)
- Loimia (1)
- Low energy QCD (1)
- Low-molecular-weight heparin (1)
- Lymphocytes (1)
- Lymphoid tissues (1)
- MDM2 (1)
- MRI (1)
- Machine learning (1)
- Massive Online Open Course (1)
- Material budget (1)
- Mechanistic (1)
- Medication Appropriateness Index (1)
- Medicinal chemistry (1)
- Membrane protein (1)
- Mesoporous silica (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Molecular diagnostics (1)
- Molecular modelling (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiple parton interactions (1)
- Myocarditis (1)
- NK cells (1)
- NMR spectroscopy (1)
- NSCLC (1)
- Nanobody (1)
- Nek1 (1)
- Neural network (1)
- Neuroepithelial tumor (1)
- Neurofeedback (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- ORL (1)
- Observation (1)
- Oncology (1)
- Oppositional defiant disorder (1)
- Otorhinolaryngology (1)
- Outcomes research (1)
- PCV (1)
- PD-L1 (1)
- PLAGL1 (1)
- PM10 (1)
- PYTHIA (1)
- Partial wave analysis (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Phage display (1)
- Pharmacology (1)
- Plant symbiosis (1)
- Plasma (1)
- Pneumocystis jirovecii (1)
- Pneumonia (1)
- Point of care (1)
- Polo-like kinase 3 (1)
- Pre-analytics (1)
- Predictive model (1)
- Primary Care Health Centre (1)
- Production Cross Section (1)
- Prognostic (1)
- Properties of Hadrons (1)
- Prostate cancer (1)
- Proteins (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Pulmonary embolism (1)
- QGP (1)
- Quality of life (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- RHIC (1)
- RITA (1)
- RNA Biology (1)
- RNA genome (1)
- RNASolution-state NMR (1)
- Randomised controlled trial (1)
- Randomized Controlled Trial (1)
- Rapidity Range (1)
- Rare diseases (1)
- Relativistic heavy ion physics (1)
- Research (1)
- Research Ethics (1)
- Residency (1)
- Residential care (1)
- Resolution Parameter (1)
- Response control (1)
- Rheumatoid Arthritis (1)
- Ribosome display (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SCCHN (1)
- SDF-1 (1)
- SEDDS (1)
- SL1 (1)
- SL5a (1)
- SL5b (1)
- SL5b + c (1)
- SL5c (1)
- SMAD (1)
- SMEDDS (1)
- SNEDDS (1)
- SPSS (1)
- Salivary gland cancer (1)
- Salivary gland carcinoma (1)
- Scientific Research (1)
- Screening (1)
- Seizure (1)
- Serum (1)
- Shell model (1)
- Single muons (1)
- Size distribution (1)
- Skills training (1)
- Slow Cortical Potentials, SCP (1)
- Small molecules (1)
- Social Control of Human Experimentation (1)
- Social Control of Science/Technology (1)
- Socio-ecology (1)
- SoftDrop (1)
- Solid dispersion (1)
- Sonography (1)
- Spanish National Health System (1)
- Specialist training (1)
- Spectroscopic factors & electromagnetic moments (1)
- Splitting function (1)
- Ste2p (1)
- Stereotactic ablative body radiotherapy (1)
- Structural biology and molecular biophysics (1)
- Supratentorial (1)
- Surgery (1)
- Survey (1)
- Sustained attention (1)
- Systematic Uncertainty (1)
- Systemic therapy (1)
- TGFβ (1)
- TR (1)
- TTFields (1)
- TUR-P (1)
- Teaching (1)
- Techniques and instrumentation (1)
- Telemedicine (1)
- Therapeutic anticoagulation (1)
- Thermal model (1)
- Time Projection Chamber (1)
- Tomography (1)
- Tools and ressources (1)
- Topology (1)
- Tracking (1)
- Transition radiation detector (1)
- Transurethral resection of the prostate (1)
- Transverse momentum (1)
- Transversity (1)
- Treatment modification (1)
- Trigger (1)
- Ultrafine particles (1)
- University hospitals (1)
- Universitätskliniken (1)
- Urban aerosol (1)
- Vaccination (1)
- Vector Boson Production (1)
- Weiterbildung (1)
- X-rays (1)
- Xenon-based gas mixture (1)
- accident (1)
- acoustic radiation force impulse (1)
- acute decompensation (1)
- acute-on-chronic liver failure (1)
- aggression (1)
- aging (1)
- algal evolution (1)
- amorphous stability (1)
- anal carcinoma (1)
- antiviral therapy (1)
- archeological modeling (1)
- artifacts (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- biogeographic legaciese (1)
- brain cancer (1)
- cART (1)
- cBioPortal (1)
- cancer (1)
- cancer-specific survival (1)
- caspase 8 (1)
- caspase-8 (1)
- chemogenomic set (1)
- chemoresistance (1)
- chromalveolate (1)
- chronic hepatitis C (1)
- cirrhosis (1)
- clinical (1)
- clinical practice (1)
- colorectal cancer (1)
- comorbidities (1)
- complex plastid (1)
- computational biology (1)
- computed tomography (1)
- computer-assisted (1)
- congenital duodenal obstruction (1)
- consensus (1)
- corneas (1)
- corticosteroids (1)
- critically ill patients (1)
- crystal structure determination (1)
- dE/dx (1)
- data quality (1)
- decision making (1)
- decision support systems (1)
- deep neural network models (1)
- deswelling (1)
- detector (1)
- dexamethasone (1)
- diffuse low-grade glioma (1)
- diffusion-weighted magnetic resonance imaging (1)
- direct-acting antiviral (DAA) treatment (1)
- disease-free survival (1)
- drug discovery (1)
- druggable genome (1)
- ectosomes (1)
- electroencephalography (EEG) (1)
- eltrombopag (1)
- emiliania huxleyi (1)
- epilepsy (1)
- excitation (1)
- exosomes (1)
- experimental results (1)
- extracellular vesicles (1)
- fMRI (1)
- fMRI/EEG (1)
- fluorine (1)
- forest classification (1)
- forest functional similarity (1)
- fractionation (1)
- fragment screening (1)
- fragment-based screening (1)
- freshwater ecosystems (1)
- gastrointestinal stromal tumours (1)
- gene signature (1)
- glass forming ability (1)
- glioblastoma survival (1)
- glioma (1)
- global change (1)
- guidelines (1)
- habitat destruction (1)
- head and neck squamous cell carcinoma (1)
- health-related quality of life (1)
- health-relatedquality of life (1)
- heavy ion experiments (1)
- hepatic encephalopathy (1)
- highly-charged ions (1)
- hotmelt extrusion (1)
- hotspot loci (1)
- human (1)
- human cytomegalovirus (1)
- human–environment interaction (1)
- hydrate (1)
- hypothesis (1)
- immune microenvironment (1)
- immunotherapy (1)
- in silico tools (1)
- injury (1)
- insect abundance (1)
- interscalene brachial plexus block (1)
- intraspecific morphological variability (1)
- iron chelation (1)
- keratoplasty (1)
- kinase inhibitor (1)
- land use (1)
- lasso regression (1)
- leukocytosis (1)
- leukopenia (1)
- lipid based formulation (1)
- lipid suspension (1)
- liver (1)
- liver cirrhosis (1)
- local anesthetic (1)
- lockdown (1)
- logistic models (1)
- long-term research (1)
- lung cancer (1)
- mRNA and protein expression (1)
- machine learning (1)
- maternal care (1)
- membrane protein (1)
- merkel cell carcinoma (1)
- mesoporous silica (1)
- metabolic syndromes (1)
- microdeletions (1)
- microkeratome (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- molecular tumor board (1)
- multicenter study (1)
- multiplexed immunofluorescence (1)
- multivariate pattern analysis (1)
- myeloperoxidase (1)
- neoadjuvant chemoradiotherapy (1)
- neoplasms (1)
- neurodegeneration (1)
- neurodevelopmental (1)
- neurological outcome (1)
- neuroscience (1)
- neutrophils (1)
- nomogram (1)
- nuclear magnetic resonance (NMR) (1)
- open science (1)
- oral cavity cancer (1)
- organic pigment (1)
- organic thin films (1)
- outcome (1)
- ovarian cancer (1)
- overall survival (1)
- p+p collisions (1)
- p16 (1)
- p53 activator (1)
- paleoclimate modeling (1)
- paleoenvironment modeling (1)
- paleoenvironment reconstruction (1)
- parameterization development (1)
- pediatric intensive care (1)
- pediatric surgery (1)
- peri-implantitis (1)
- phenotypic screening (1)
- phylogenetic community distance (1)
- plastid protein import (1)
- polo-like kinase 1 (1)
- polo-like kinase 3 (1)
- polymers (1)
- polyomavirus (MCPyV) (1)
- portosystemic shunt (1)
- postnatal care (1)
- postoperative radiochemotherapy (1)
- postoperative radiotherapy (1)
- ppK − (1)
- precipitation inhibitor (1)
- precision medicine (1)
- predictive (1)
- predictive biomarker (1)
- prenatal diagnostic (1)
- prognosis (1)
- prognostic (1)
- prognostic biomarker (1)
- prognostic marker (1)
- propensity score matching (1)
- protein folding (1)
- protein kinase (1)
- proteins (1)
- pulmonary embolism (1)
- quark gluon plasma (1)
- radiation (1)
- radioimmunotherpay (1)
- radiosensitization (1)
- real-world structure (1)
- recurrence pattern (1)
- relativistic collisions (1)
- reproducibility (1)
- requirements analysis (1)
- resilience (1)
- retrospective trial (1)
- rigor (1)
- sarcoma (1)
- sarcopenia (1)
- scene representation (1)
- secondary endosymbiosis (1)
- selenolates (1)
- self-assembled monolayers (1)
- short molecular distance (1)
- single-column mode (1)
- small molecules (1)
- solvate (1)
- spectra (1)
- spontaneous portosystemic shunt (1)
- standardization (1)
- storage rings (1)
- structural biology (1)
- super-SMEDDS (1)
- super-SNEDDS (1)
- supersaturating drug delivery systems (1)
- survival (1)
- temozolomide (1)
- therapeutic anticoagulation (1)
- thiolates (1)
- threats (1)
- thrombopenia (1)
- thrombopietin receptor agonist (1)
- toxic hemisphere syndrome (1)
- toxicity (1)
- transient elastography (1)
- translational investigation (1)
- trauma (1)
- triptycene (1)
- tropical forests (1)
- tumor microenvironment (1)
- tumor-infiltrating-lymphocytes (1)
- tyrosine kinase inhibitors (1)
- understudied kinase (1)
- validation (1)
- venetoclax (1)
- ventral striatum (1)
- visual perception (1)
- xenograft (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1129)
- Frankfurt Institute for Advanced Studies (FIAS) (992)
- Informatik (921)
- Medizin (88)
- Geowissenschaften (16)
- Biochemie, Chemie und Pharmazie (14)
- Biowissenschaften (11)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (8)
- Biochemie und Chemie (7)
- Institut für Ökologie, Evolution und Diversität (5)
Background Microdeletions are known to confer risk to epilepsy, particularly at genomic rearrangement “hotspot” loci. However, deciphering their role outside hotspots and risk assessment by epilepsy sub-type has not been conducted.
Methods We assessed the burden, frequency and genomic content of rare, large microdeletions found in a previously published cohort of 1,366 patients with Genetic Generalized Epilepsy (GGE) plus two sets of additional unpublished genome-wide microdeletions found in 281 Rolandic Epilepsy (RE) and 807 Adult Focal Epilepsy (AFE) patients, totaling 2,454 cases. These microdeletion sets were assessed in a combined analysis and in sub-type specific approaches against 6,746 ethnically matched controls.
Results When hotspots are considered, we detected an enrichment of microdeletions in the combined epilepsy analysis (adjusted-P= 2.00×10-7; OR = 1.89; 95%-CI: 1.51-2.35), where the implicated microdeletions overlapped with rarely deleted genes and those involved in neurodevelopmental processes. Sub-type specific analyses showed that hotspot deletions in the GGE subgroup contribute most of the signal (adjusted-P = 1.22×10-12; OR = 7.45; 95%-CI = 4.20-11.97). Outside hotspot loci, microdeletions were enriched in the GGE cohort for neurodevelopmental genes (adjusted-P = 4.78×10-3; OR = 2.30; 95%-CI = 1.42-3.70), whereas no additional signal was observed for RE and AFE. Still, gene content analysis was able to identify known (NRXN1, RBFOX1 and PCDH7) and novel (LOC102723362) candidate genes affected in more than one epilepsy sub-type but not in controls.
Conclusions Our results show a heterogeneous effect of recurrent and non-recurrent microdeletions as part of the genetic architecture of GGE and a minor to negligible contribution in the etiology of RE and AFE.
Background: To study neoadjuvant chemoradiotherapy (nCRT) and potential predictive factors for response in locally advanced oral cavity cancer (LA-OCC).
Methods: The INVERT trial is an ongoing single-center, prospective phase 2, proof-of-principle trial. Operable patients with stage III-IVA squamous cell carcinomas of the oral cavity were eligible and received nCRT consisting of 60 Gy with concomitant cisplatin and 5-fluorouracil. Surgery was scheduled 6-8 weeks after completion of nCRT. Explorative, multiplex immunohistochemistry (IHC) was performed on pretreatment tumor specimen, and diffusion-weighted magnetic resonance imaging (DW-MRI) was conducted prior to, during nCRT (day 15), and before surgery to identify potential predictive biomarkers and imaging features. Primary endpoint was the pathological complete response (pCR) rate.
Results: Seventeen patients with stage IVA OCC were included in this interim analysis. All patients completed nCRT. One patient died from pneumonia 10 weeks after nCRT before surgery. Complete tumor resection (R0) was achieved in 16/17 patients, of whom 7 (41%, 95% CI: 18-67%) showed pCR. According to the Clavien-Dindo classification, grade 3a and 3b complications were found in 4 (25%) and 5 (31%) patients, respectively; grade 4-5 complications did not occur. Increased changes in the apparent diffusion coefficient signal intensities between MRI at day 15 of nCRT and before surgery were associated with better response (p=0.022). Higher abundances of programmed cell death protein 1 (PD1) positive cytotoxic T-cells (p=0.012), PD1+ macrophages (p=0.046), and cancer-associated fibroblasts (CAFs, p=0.036) were associated with incomplete response to nCRT.
Conclusion: nCRT for LA-OCC followed by radical surgery is feasible and shows high response rates. Larger patient cohorts from randomized trials are needed to further investigate nCRT and predictive biomarkers such as changes in DW-MRI signal intensities, tumor infiltrating immune cells, and CAFs.
Children’s and adolescents’ lives drastically changed during COVID lockdowns worldwide. To compare accident- and injury-related admissions to pediatric intensive care units (PICU) during the first German COVID lockdown with previous years, we conducted a retrospective multicenter study among 37 PICUs (21.5% of German PICU capacities). A total of 1444 admissions after accidents or injuries during the first lockdown period and matched periods of 2017–2019 were reported and standardized morbidity ratios (SMR) were calculated. Total PICU admissions due to accidents/injuries declined from an average of 366 to 346 (SMR 0.95 (CI 0.85–1.05)). Admissions with trauma increased from 196 to 212 (1.07 (0.93–1.23). Traffic accidents and school/kindergarten accidents decreased (0.77 (0.57–1.02 and 0.26 (0.05–0.75)), whereas household and leisure accidents increased (1.33 (1.06–1.66) and 1.34 (1.06–1.67)). Less neurosurgeries and more visceral surgeries were performed (0.69 (0.38–1.16) and 2.09 (1.19–3.39)). Non-accidental non-suicidal injuries declined (0.73 (0.42–1.17)). Suicide attempts increased in adolescent boys (1.38 (0.51–3.02)), but decreased in adolescent girls (0.56 (0.32–0.79)). In summary, changed trauma mechanisms entailed different surgeries compared to previous years. We found no evidence for an increase in child abuse cases requiring intensive care. The increase in suicide attempts among boys demands investigation.
Introduction: Dravet syndrome (DS) is a rare developmental and epileptic encephalopathy. This study estimated cost, cost-driving factors and quality of life (QoL) in patients with Dravet syndrome and their caregivers in a prospective, multicenter study in Germany.
Methods: A validated 3–12-month retrospective questionnaire and a prospective 3-month diary assessing clinical characteristics, QoL, and direct, indirect and out-of-pocket (OOP) costs were administered to caregivers of patients with DS throughout Germany.
Results: Caregivers of 93 patients (mean age 10.1 years, ±7.1, range 15 months–33.7 years) submitted questionnaires and 77 prospective diaries. The majority of patients (95%) experienced at least one seizure during the previous 12 months and 77% a status epilepticus (SE) at least once in their lives. Over 70% of patients had behavioural problems and delayed speech development and over 80% attention deficit symptoms and disturbance of motor skills and movement coordination. Patient QoL was lower than in the general population and 45% of caregivers had some form of depressive symptoms. Direct health care costs per three months were a mean of €6,043 ± €5,825 (median €4054, CI €4935-€7350) per patient. Inpatient costs formed the single most important cost category (28%, €1,702 ± €4,315), followed by care grade benefits (19%, €1,130 ± €805), anti-epileptic drug (AED) costs (15%, €892 ± €1,017) and ancillary treatments (9%, €559 ± €503). Total indirect costs were €4,399 ±€ 4,989 (median €0, CI €3466-€5551) in mothers and €391 ± €1,352 (median €0, CI €195-€841) in fathers. In univariate analysis seizure frequency, experience of SE, nursing care level and severe additional symptoms were found to be associated with total direct healthcare costs. Severe additional symptoms was the single independently significant explanatory factor in a multivariate analysis.
Conclusions: This study over a period up to 15 months revealed substantial direct and indirect healthcare costs of DS in Germany and highlights the relatively low patient and caregiver QoL compared with the general population.
Ependymomas encompass a heterogeneous group of central nervous system (CNS) neoplasms that occur along the entire neuroaxis. In recent years, extensive (epi-)genomic profiling efforts have identified several molecular groups of ependymoma that are characterized by distinct molecular alterations and/or patterns. Based on unsupervised visualization of a large cohort of genome-wide DNA methylation data, we identified a highly distinct group of pediatric-type tumors (n = 40) forming a cluster separate from all established CNS tumor types, of which a high proportion were histopathologically diagnosed as ependymoma. RNA sequencing revealed recurrent fusions involving the pleomorphic adenoma gene-like 1 (PLAGL1) gene in 19 of 20 of the samples analyzed, with the most common fusion being EWSR1:PLAGL1 (n = 13). Five tumors showed a PLAGL1:FOXO1 fusion and one a PLAGL1:EP300 fusion. High transcript levels of PLAGL1 were noted in these tumors, with concurrent overexpression of the imprinted genes H19 and IGF2, which are regulated by PLAGL1. Histopathological review of cases with sufficient material (n = 16) demonstrated a broad morphological spectrum of tumors with predominant ependymoma-like features. Immunohistochemically, tumors were GFAP positive and OLIG2- and SOX10 negative. In 3/16 of the cases, a dot-like positivity for EMA was detected. All tumors in our series were located in the supratentorial compartment. Median age of the patients at the time of diagnosis was 6.2 years. Median progression-free survival was 35 months (for 11 patients with data available). In summary, our findings suggest the existence of a novel group of supratentorial neuroepithelial tumors that are characterized by recurrent PLAGL1 fusions and enriched for pediatric patients.
In recent years, there have been prominent calls for a new social contract that accords a more central role to citizens in health research. Typically, this has been understood as citizens and patients having a greater voice and role within the standard research enterprise. Beyond this, however, it is important that the renegotiated contract specifically addresses the oversight of a new, path-breaking approach to health research: participant-led research. In light of the momentum behind participant-led research and its potential to advance health knowledge by challenging and complementing traditional research, it is vital for all stakeholders to work together in securing the conditions that will enable it to flourish.
Background: Dexamethasone (Dex) is the most common corticosteroid to treat edema in glioblastoma (GBM) patients. Recent studies identified the addition of Dex to radiation therapy (RT) to be associated with poor survival. Independently, Tumor Treating Fields (TTFields) provides a novel anti-cancer modality for patients with primary and recurrent GBM. Whether Dex influences the efficacy of TTFields, however, remains elusive.
Methods: Human GBM cell lines MZ54 and U251 were treated with RT or TTFields in combination with Dex and the effects on cell counts and cell death were determined via flow cytometry. We further performed a retrospective analysis of GBM patients with TTFields treatment +/- concomitant Dex and analysed its impact on progression-free (PFS) and overall survival (OS).
Results: The addition of Dex significantly reduced the efficacy of RT in U251 and MZ54 cells. TTFields (200 kHz/250 kHz) induced massive cell death in both cell lines. Concomitant treatment of TTFields and Dex did not reduce the overall efficacy of TTFields. Further, in our retrospective clinical analysis, we found that the addition of Dex to TTFields therapy did not influence PFS nor OS.
Conclusion: Our translational investigation indicates that the efficacy of TTFields therapy in patients with GBM and primary GBM cell lines is not affected by the addition of Dex.
Purpose: Dexamethasone (Dex) is the most common corticosteroid to treat edema in glioblastoma (GBM) patients. Recent studies identified the addition of Dex to radiation therapy (RT) to be associated with poor survival. Independently, Tumor Treating Fields (TTFields) provides a novel anti-cancer modality for patients with primary and recurrent GBM. Whether Dex influences the efficacy of TTFields, however, remains elusive. Methods: Human GBM cell lines MZ54 and U251 were treated with RT or TTFields in combination with Dex and the effects on cell counts and cell death were determined via flow cytometry. We further performed a retrospective analysis of GBM patients with TTFields treatment +/- concomitant Dex and analysed its impact on progression-free (PFS) and overall survival (OS). Results: The addition of Dex significantly reduced the efficacy of RT in U251, but not in MZ54 cells. TTFields (200 kHz/250 kHz) induced massive cell death in both cell lines. Concomitant treatment of TTFields and Dex did not reduce the overall efficacy of TTFields. Further, in our retrospective clinical analysis, we found that the addition of Dex to TTFields therapy did not influence PFS nor OS. Conclusion: Our translational investigation indicates that the efficacy of TTFields therapy in patients with GBM and GBM cell lines is not affected by the addition of Dex.
Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date, only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-label. A retrospective cohort analysis of patients with GBM and postoperative, thoracic CT scan confirmed PE was performed. Clinical course, follow-up at 6 and 12 months and the overall survival (OS) were evaluated using medical charts and neuroradiological data. Out of 584 GBM patients, 8% suffered from postoperative PE. Out of these, 30% received direct oral anticoagulants (DOACs) and 70% low-molecular-weight heparin (LMWH) for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis, or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6 and 12 months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS. In our analysis, DOACs showed a satisfactory safety profile in terms of major ICH, re-thrombosis, and re-embolism compared to LMWH in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.
Chemotherapy and diffuse low-grade gliomas : a survey within the European Low-Grade Glioma Network
(2018)
Background: Diffuse low-grade gliomas (DLGGs) are rare and incurable tumors. Whereas maximal safe, functional-based surgical resection is the first-line treatment, the timing and choice of further treatments (chemotherapy, radiation therapy, or combined treatments) remain controversial.
Methods: An online survey on the management of DLGG patients was sent to 28 expert centers from the European Low-Grade Glioma Network (ELGGN) in May 2015. It contained 40 specific questions addressing the modalities of use of chemotherapy in these patients.
Results: The survey demonstrated a significant heterogeneity in practice regarding the initial management of DLGG patients and the use of chemotherapy. Interestingly, radiation therapy combined with the procarbazine, CCNU (lomustine), and vincristine regimen has not imposed itself as the gold-standard treatment after surgery, despite the results of the Radiation Therapy Oncology Group 9802 study. Temozolomide is largely used as first-line treatment after surgical resection for high-risk DLGG patients, or at progression.
Conclusions: The heterogeneity in the management of patients with DLGG demonstrates that many questions regarding the postoperative strategy and the use of chemotherapy remain unanswered. Our survey reveals a high recruitment potential within the ELGGN for retrospective or prospective studies to generate new data regarding these issues.
Background: Glioblastoma (GBM) patients are at particularly high risk for thrombotic complications. In the event of a postoperative pulmonary embolism, therapeutic anticoagulation (tAC) is indispensable. The impact of therapeutic anticoagulation on recurrence pattern in GBM is currently unknown. Methods: We conducted a matched-pair cohort analysis of 57 GBM patients with or without tAC that were matched for age, sex, gross total resection and MGMT methylation status in a ratio of 1:2. Patients’ characteristics and clinical course were evaluated using medical charts. MRI characteristics were evaluated by two independent authors blinded to the AC status. Results: The morphologic MRI appearance in first GBM recurrence showed a significantly higher presence of multifocal, midline crossing and sharp demarcated GBM recurrence patterns in patients with therapeutic tAC compared to the matched control group. Although statistically non-significant, the therapeutic tAC cohort showed increased survival. Conclusion: Therapeutic anticoagulation induced significant morphologic changes in GBM recurrences. The underlying pathophysiology is discussed in this article but remains to be further elucidated.
Purpose: Seizures pose a significant burden in patients with primary and secondary brain tumors during the end-of-life period. A wide range of 6 to 56% of clinically observed epileptic seizures at the end of life has been reported. We aimed to analyse the incidence of epileptic seizures at the end of life in brain tumor patients more accurately using not only clinical but also electrophysiological findings.
Methods: This retrospective, single center study included brain tumor patients who died during the stay on the ward or within 7 days after discharge between 01/2015 and 08/2020. Clinical observation of seizures derived from the original medical records and EEG findings (within 45 days prior to death) were analyzed to determine the incidence of seizures in that period.
Results: Of the 68 eligible patients, 50 patients (73.5%) suffered from seizures within 45 days prior to death, of which n = 24 had a status epilepticus. The diagnosis of seizures/ status epilepticus was determined either by the presentation of clinical signs in 45 patients and if not, by the detection of a (possible) non-convulsive status epilepticus in the EEG of five patients.
Conclusion: In the presence of neurologically trained staff and with the frequent use of routine EEG, we were able to identify seizures and to distinguish status epilepticus from encephalopathy/ hypoactive delirium. We detected a higher incidence of seizures and status epilepticus at the end of life in neurooncological patients than previously reported.
Background: Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-label.
Methods: A retrospective cohort analysis of patients with GBM and postoperative, thoracic CT-scan confirmed, PE was performed. Clinical course, follow-up at 6 and 12 months and the overall survival (OS) were evaluated using medical charts and neuroradiological data.
Results: Out of 584 GBM patients, 8% suffered from postoperative PE. Out of theses, 30% received direct oral anticoagulants (DOACs) and 70% low-molecular-weight heparin (LMWH) for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6- and 12 months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS.
Conclusion: In our analysis DOACs showed a satisfactory safety profile in terms of major ICH, re-thrombosis and re-embolism compared to LMWH in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.
The Kinase Chemogenomic Set (KCGS): an open science resource for kinase vulnerability identification
(2021)
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS), current Version 1.0, is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.
The nsP3 macrodomain is a conserved protein interaction module that plays essential regulatory roles in host immune response by recognizing and removing posttranslational ADP-ribosylation sites during SARS-CoV-2 infection. Thus, targeting this protein domain may offer a therapeutic strategy to combat the current and future virus pandemics. To assist inhibitor development efforts, we report here a comprehensive set of macrodomain crystal structures complexed with diverse naturally-occurring nucleotides, small molecules as well as nucleotide analogues including GS-441524 and its phosphorylated analogue, active metabolites of remdesivir. The presented data strengthen our understanding of the SARS-CoV-2 macrodomain structural plasticity and it provides chemical starting points for future inhibitor development.
Background: In Europe, the number of females exhibiting oppositional defiant disorder (ODD) and conduct disorder (CD) is growing. Many of these females live in youth welfare institutions. Consequently, there is a great need for evidence-based interventions within youth welfare settings. A recently developed approach targeting the specific needs of girls with ODD and CD in residential care is START NOW. The aim of this group-based behavioural skills training programme is to specifically enhance emotional regulation capacities to enable females with CD or ODD to appropriately deal with daily-life demands. It is intended to enhance psychosocial adjustment and well-being as well as reduce oppositional and aggressive behaviour. We present the study protocol (version 4.1; 10 February 2016) of the FemNAT-CD intervention trial titled "Group-Based Treatment of Adolescent Female Conduct Disorders: The Central Role of Emotion Regulation".
Methods/design: The study is a prospective, confirmatory, cluster-randomised, parallel-group, multi-centre, randomised controlled trial with 128 institutionalised female adolescents who fulfil the diagnostic criteria of ODD and/or CD. Institutions/wards will be randomised either to provide the 12-week skills training as an add-on intervention or to provide treatment as usual. Once the first cycle is completed, each institution will run a second cycle with the opposite condition. Primary endpoints are the pre-post change in number of CD/ODD symptoms as assessed by a standardised, semi-structured psychiatric interview (Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children–Present and Lifetime, CD/ODD section) between baseline and the end of intervention, as well as between baseline and a 3-month follow-up point. Secondary objectives include pre-post change in CD/ODD-related outcome measures, most notably emotional regulation on a behavioural and neurobiological level after completion of START NOW compared with treatment as usual.
Discussion: To our knowledge, this study is the first to date to systematically investigate the effectiveness of an adapted integrative psychosocial intervention designed for female adolescents with ODD and CD in youth welfare settings.
Trial registration: German Clinical Trials Register (DRKS) identifier: DRKS00007524. Registered on 18 December 2015 and with the World Health Organisation International Clinical Trials Registry Platform.